Cogstate Ltd (AU:CGS)
ASX:CGS
Want to see AU:CGS full AI Analyst Report?
CGS Stock Chart & Stats
AU$2.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.21 - AU$2.97
Previous CloseN/A
Volume30.50K
Average Volume (3M)355.93K
Market Cap
AU$410.39M
Enterprise ValueAU$296.16M
Total Cash (Recent Filing)AU$34.07M
Total Debt (Recent Filing)AU$716.74K
Price to Earnings (P/E)20.9
Beta0.05
Next Earnings
Aug 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield0.88%
Share Statistics
EPS (TTM)0.09
Shares Outstanding170,994,020
10 Day Avg. Volume327,690
30 Day Avg. Volume355,934
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)6.26
Price to Sales (P/S)5.90
P/FCF Ratio35.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.18Price Target Upside25.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)AU$59.80M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a high equity ratio give Cogstate durable financial flexibility to fund trials, invest in technology and absorb timing lags in clinical revenue recognition. Strong ROE shows efficient capital use, supporting strategic optionality and lower refinancing risk over the medium term.
High Gross And Net MarginsSustained ~60% gross margin and ~20% net margin indicate strong unit economics for cognitive assessment services. These margins create a structural earnings buffer to fund selective investment (delivery, AI) while maintaining profitability even if revenue recognition is lumpy across clinical trial cycles.
Backlog And Contracted Revenue VisibilityA $92M backlog and rising contracted revenue for upcoming halves provide tangible forward revenue visibility tied to multi-visit trials. This pipeline, plus strong channel partner contribution, underpins predictable demand for delivery capacity and supports conversion into H2/FY27 revenue as studies progress.
Bears Say
Revenue And Free Cash Flow DeclineA steep 34% revenue drop and 50% FCF decline materially reduce internal funding for growth and make outcomes sensitive to trial timing. With revenue tied to sponsor study activity, these decreases constrain reinvestment, hiring cadence and the firm's ability to smooth investment over 2–6 months.
Concentration Risk In Core IndicationHeavy exposure to large presymptomatic Alzheimer’s programs creates structural revenue volatility: long, lumpy trials can produce periods of high visibility but also sudden troughs when activity slows. This boom‑and‑bust dynamic elevates booking and recognition risk until diversification progresses.
Margin Pressure From Scaling DeliveryManagement increased delivery headcount and reclassified science resources into cost of sales to support growth, which compressed reported margins. If these higher operating costs persist or scale inefficiently, margin recovery will be slower and comparability to prior periods more difficult.
Cogstate Ltd News
CGS FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest share price was AU$1.21 and its highest was AU$2.97 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is AU$410.39M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 114 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Feb 18, 2026. The company reported AU$0.036 earnings per share for the quarter, beating the consensus estimate of AU$0.029 by AU$0.007.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of AU$0.02 which represents an annual dividend yield of 0.88%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.05.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 170,994,020 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of AU$0.036 in its last earnings report, beating expectations of AU$0.029. Following the earnings report the stock price went up 8.716%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in AU:CGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.18 (25.49% Upside)
AU$3.18 (25.49% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
29.05%
Trailing 12-Months
Asset Growth
12.30%
Trailing 12-Months
Company Description
Cogstate Ltd
Cogstate Ltd (CGS) is a global neuroscience technology company focused on the development and commercialization of cognitive assessment tools and solutions. Operating primarily within the healthcare and pharmaceutical sectors, Cogstate specializes in providing cognitive testing services that are used in clinical trials and clinical practice to measure cognitive function in various populations, including patients with neurological disorders and those undergoing drug trials. The company's core products include digital cognitive assessments that facilitate the evaluation of cognitive performance and the monitoring of cognitive health over time.
CGS Company Deck
CGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.View all AU:CGS earnings summariesCGS Stock 12 Month Forecast
Average Price Target
AU$3.18
▲(25.49% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---